Samyang Holdings is an API manufacturer based in South Korea. It holds one active US drug master file and one valid CEP across a filed portfolio of 2 molecules. Its filings concentrate with NPRA (MY) and ARCSA (EC).
| Site | FDA FEI |
|---|---|
| DAEJEON, South Korea | Not on file |
| Gyeonggi-do, South Korea | Not on file |
| Molecule | Regulators | Docs |
|---|---|---|
| Docetaxel | EDQM | 1 |
| Paclitaxel | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| NPRA (MY) | 9 | None |
| ARCSA (EC) | 1 | None |
Choose your molecules and target markets. Samyang Holdings comes back tiered against every other supplier able to file there.
Start for free